



## Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- [Dyne Therapeutics, Inc.](https://www.dyne-tx.com) (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET).

A live webcast will be available in the Investors & Media section of Dyne's website at <https://investors.dyne-tx.com/news-and-events/events-and-presentations> and a replay will be accessible for 30 days following the presentation.

### About Dyne Therapeutics

Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit <https://www.dyne-tx.com/>, and follow us on [X](#), [LinkedIn](#) and [Facebook](#).

### Contacts:

#### Investors

Mike Hencke  
Kendall Investor Relations  
[ir@dyne-tx.com](mailto:ir@dyne-tx.com)

#### Media

Stacy Nartker  
Dyne Therapeutics  
[snartker@dyne-tx.com](mailto:snartker@dyne-tx.com)  
781-317-1938